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PURPOSE OF STUDY
Stability of a pharmaceutical product may be defined as the capability of a 
particular formulation, in a specific container/closure system, to remain within its 
physical, chemical, microbiological, therapeutic and toxicological specifications. 
Drug  stability  and  compatibility  are  critical  issues  controlling  accurate  and 
appropriate delivery of drug therapy to patients.  Stability is very important for 
antibacterial agents especially those given by I .V route as they reach systemic 
circulation directly, and the clinical outcome and safety are directly correlated to 
drug levels in blood.
 
Ciprofloxacin  and  Metronidazole  are  extensively  used  intravenous 
antimicrobial  agents.  The  parenteral  admixture  of  ciprofloxacin  with 
metronidazole  is  considered  as  a  valuable  tool  for  antibacterial  therapy  when 
combined aerobic and anaerobic infections are involved (E. Vega et al. 2001). 
Peritonitis  remains  a  significant  cause  of  morbidity  and  mortality  in 
Peritoneal  Dialysis  (PD)  patients  who  need  parenteral  antibiotics  to  be  given 
along with the PD solution.  Ciprofloxacin is one of the important antibacterial 
agents used in peritonitis (Mawhinney WM et.al.1992).
Most  monograph literature  on ciprofloxacin  and metronidazole  indicate 
stability of the two drugs at room temperature (25º C) and refrigeration (5º C). 
But in a temperate country like India, temperature reaches up to 50º C in summer. 
Hence we were interested in studying the stability of ciprofloxacin-metronidazole 
I.V admixture and the stability of ciprofloxacin in peritoneal dialysis solution at 
higher temperature (45ºC) by stability indicating assay method.
 In the case of ciprofloxacin-metronidazole I.V admixture, both the drugs 
were  monitored  simultaneously  using  a  stability  indicating  first  derivative 
spectrophotometric method and the I.V admixture could be used successfully in 
clinical  therapy  of  mixed  aerobic-anaerobic  infections  if  it  was  proved  to  be 
stable.  Similarly,  stability  of  ciprofloxacin  in  peritoneal  dialysis  solution  was 
studied using stability indicating HPTLC method, in addition to a microbiological 
assay which is a direct measure of the biological activity of antimicrobial agents. 
             
ABSTRACT OF WORK DONE
The physical and chemical stability of Ciprofloxacin I.V- Metronidazole 
I.V and Ciprofloxacin-Metronidazole I.V admixture were individually determined 
at 45oC, 25oC and 5oC. Ciprofloxacin and Metronidazole were quantified by using 
a stability indicating first derivative UV spectrophotometric method (E.Vega et.al; 
2001
The physical and chemical stability of Ciprofloxacin when admixed with 
Peritoneal  Dialysis  (PD)  solution  was  determined  at  45oC,  25oC and  5oC and 
quantified by using a stability indicating HPTLC method (Jan Krzek et.al; 2005) 
in addition to a microbiological assay using E.coli – NCIM 2911 as test organism.
Decrease  in  drug  concentration  by  more  than  10%  from  initial 
concentration (0 time) was considered unstable (chemical instability). Change in 
pH by more than 1 unit  was considered unstable  (physical  instability)  (Narine 
Baririan et.al, 2003).
The drug solution was clear and colorless, but the pH decreased with time, 
though not to the extent of being considered physically unstable.
First  derivative  UV  spectrophotometric  analysis  indicated  that  2mg/ml 
concentration  of  Ciprofloxacin  I.V  when  tested  alone  maintained  adequate 
stability for 4 hours at 45oC, for 24 hours at  25oC and up to120 hours at 5oC. 
5mg/ml concentration of Metronidazole alone maintained adequate stability for 6 
hours  at  45oC, for  24 hours  at  25oC and up to  120 hours  at  5oC and the I.V 
admixture of ciprofloxacin with metronidazole (1:2.5) was stable for less than 4 
hours at 45oC, for 24 hours at 25oC and up to 120 hours at 5oC. 
HPTLC analysis  indicated that  400µg/ml concentration of ciprofloxacin 
I.V in peritoneal  dialysis  solution maintained adequate  stability  for 4 hours  at 
45oC, for 24 hours at 25oC and up to 120 hours at 5oC. As per microbiological 
assay,  Ciprofloxacin  in  peritoneal  dialysis  solution  was stable  up to  the  study 
period of 6 hours at all the three temperatures.
INTRODUCTION
Stability of a pharmaceutical product may be defined as the capability of a 
particular  formulation,  in  a  specific  container,  to  remain  within  its  physical, 
chemical, microbiological, therapeutic and toxicological specification (USP 22). 
USP (22) defines stability as the extent to which products retains within 
specified limits and throughout its period of storage and use i.e. its shelf life, the 
same properties and characteristics that it possessed at the time of manufacture.
Stability  of  a  drug  can  also  be  defined  as  the  time  from  the  date  of 
manufacture  and packaging of  the formulation  until  its  chemical  or  biological 
activity is not less than a pre-determined level of labeled potency and its physical 
characteristics have not changed appreciably or deleteriously.
REASONS BEHIND STABILITY STUDY: (Pulok. K.Mukherjee. 
et.al., 1994)
Pharmacists  have  to  play  a  vital  role  in  respect  of  stability  of  the 
pharmaceuticals as:
a) For the safety of the patient, it is important to note that the patient must 
have  to  receive  an  uniform dose  of  drug  throughout  the  shelf  life  of  the 
product.  Although a drug may have been shown to be safe for use, this is not 
necessarily  true  of  the  decomposed  products.  Manufacturers  must  have  to 
minimize or prevent decomposition of products.
b) Consideration must be given to the relevant legal requirements concerned 
with identity, strength, purity and quality of the drug.
c) It  is  important  to  prevent  the  economic  repercussions  of  marketing  an 
unstable product.
d) In any rational design and evaluation of dosage form, the stability of the 
active  component  must  be  a  major  criterion  in  determining  acceptance  or 
rejection of trial formulations.  Several forms of instability that can lead to 
rejection of a drug product are:
• With the advancement of medicinal chemistry,  drugs being used are 
highly specific, chemically complex, and potent and most of them have 
a  very narrow therapeutic  range.   If  there is  an extensive  chemical 
degradation of the active drug, it leads to a substantial lowering of the 
quantity of the therapeutic agent in the dosage form.  In these cases it 
is of paramount responsibility of the pharmacists, to see that the drug 
dosage form can reproducibly deliver the same amount of drug.
• A very toxic product may be formed in the decomposition process. 
There  the  decomposed  products  are  more  toxic  than  the  original 
therapeutic agent, which when ingested, can cause undesirable effects. 
(E.g.) p-amino-salicylic acid to m-aminophenol.
• Instability of a drug product may lead to decrease in bioavailability. 
This reduction in bioavailability can lead to a substantial lowering in 
the therapeutic efficacy of the dosage form.  This phenomenon may be 
due to physical  and chemical  changes of the diluents in the dosage 
form,  independent  of  whatever  changes  the  active  drug  may  have 
undergone.
• There may be substantial  changes in the physical  appearance of the 
dosage form. This may not alter the therapeutic efficacy of the dosage 
form but most likely may result in loss of confidence of the patient in 
the drug product, which then has to be rejected.
Incompatibility (Levit J Demorest. et.al, 1986)       
   
The phenomenon of incompatibility occurs when the LVP (large volume 
parenteral)  and  drug  produce,  by  physicochemical  means,  a  product  that  is 
unsuitable  for  administration  to  the  patient.  Physical  incompatibility  may  be 
detected by a change in the appearance of the solution, such as the formation of a 
precipitate,  a haze,  a change of color,  or  the breaking of  an emulsion,  Subtle 
incompatibilities, such as a change in pH or drug concentration, may not result in 
a visual change or may not become evident until a later time.
Instability occurs when an LVP product or admixture is modified due to 
sorption or such storage conditions as time, light, or temperature. The modified 
product may not be suitable for administration, and unless the combination has 
been studied in the laboratory, the only clue to a stability problem may be failure 
to get the expected clinical result.
The parameters of tonicity,  pH, solubility,  and added substances,  which 
were  considerations  in  the  design  of  the  LVP  formulation,  also  must  be 
considered in a different context when drugs are added to the solution. The drug 
product  may  contain  solvents,  preservatives,  stabilizers,  buffers,  and  other 
ingredients that, when added in the LVP can result in instability and compatibility 
problem. Sodium benzoate, a preservative in some drugs precipitates as benzoic 
acid when added to an LVP with an acidic pH. Copper a trace metal needed by the 
body.  Can cause precipitation in amino acid solution.  The pharmacist  must be 
knowledgeable of the ingredients in the LVP and in the drug product and possible 
incompatibilities when preparing admixtures.
Stability of the combination must be maintained after mixing and during 
infusion if the desired result is to be achieved. Stability problems may be caused 
by  pH,  solubility,  sensitivity  to  light  or  temperature,  absorption,  or  chemical 
incompatibility. Stability may also be related to time, and this is one reason that is  
recommended that admixtures not be stored for prolonged periods.
One example of the role of pH would be that be that of ampicillin B in 
dextrose solutions. Unless the pH of the dextrose solution is greater than 5.0, the 
combination is incompatible. The monograph for Dextrose for injection allows a 
pH range of  3.5 – 6.5.  When the    pH of  5% Dextrose in  Lactated  Ringer’s 
injection is below 5, some nerve blocking agents, such as succinylcholine, will 
precipitate from solution.
Chemotherapeutic  drugs  and  vitamin  preparations  generally  should  be 
protected from light.
Sodium bisulfite, an ingredient added to some LVP to reduce degradation 
caused by oxidation, may be present in only the quantity needed for protection of 
the solution during sterilization and shelf life. It may not be present in sufficient 
quantity to provide protection from the air that may be introduced to the container 
during admixing or storage in plastic containers.
The order of introduction  of drugs to the LVP may either  highlight  or 
mask visible incompatibilities. If a drug is incompatible at a give pH and the pH 
of the LVP must be adjusted, the pH should be adjusted before the drug is added. 
A fat emulsion, white and opaque, masks reaction that might be visible in a clear 
solution and the package insert  cautions  not to add electrolytes  directly to the 
emulsion.
Types of Incompatibilities:
Incompatibilities  can  be  divided  into  three  categories:  therapeutic 
(pharmacologic),  physical  and  chemical.  “Therapeutic  incompatibilities”  occur 
when  two  or  more  drugs  administered  concurrently  result  in  undesirable 
antagonistic  or synergistic pharmacologic action.  Examples of incompatibilities 
are the antagonism between chloramphenicol  and penicillin  and the possibility 
that penicillin or cortisone may antagonize the effect of heparin and produce a 
misleading picture of the anticoagulant effect of heparin.
When the combination of two or more drugs in solution results in a change 
in  the  appearance  of  the  solution,  such  as  a  change  in  colour,  formation  of 
turbidity  or  precipitate,  or  the  evolution  of  a  gas,  it  is  called  a  “physical 
incompatibility”. Physical incompatibilities are the easiest to detect and represent 
the types most familiar to hospital pharmacists. They can frequently be predicted 
from the chemical characteristics of the drugs involved. For example, the sodium 
salts of weak acids such as sodium diphenylhydantoin or sodium phenobarbital 
precipitate as free acids when added to intravenous fluids having an acidic pH. 
Available compatibility charts attempt to outline this type of incompatibility.
Degradation  of  drugs  in  solution  resulting  from  the  combination  of 
parenteral dosage forms is called “Chemical incompatibility”. This is an arbitrary 
classification  because  physical  incompatibilities  also  result  from  chemical 
changes.  Most  chemical  incompatibilities  result  from  hydrolysis,  oxidation, 
reduction  or  complexation  and  can  be  detected  only  with  suitable  analytical 
methods.
Reasons for Incompatibility (Salvatore J. Turco,  
2000):
Probably  the  greatest  single  factor  in  causing  an  incompatibility  is  a 
change in acid – base environment. The solubility and stability of a drug may vary 
as the pH of solution varies. A change in the pH may be a clue in predicting an 
incompatibility, especially one involving drug stability, since it is not necessarily 
apparent physically.
Penicillin provides a good example of the effect of pH on drug stability. 
The antibiotic in solution remains active for 24 hours at pH 6.5, but at pH 3.4 is 
destroyed  in  a  short  time.  Potassium  penicillin  G  contains  a  citrate  buffer; 
therefore, the injection is buffered at pH 6.0 to 6.5 when reconstituted with sterile 
water  for  injection,  5%  D/W,  or  sodium  chloride  injection.  When  this 
reconstituted solution is added to an intravenous fluid such as dextrose Injection 
of sodium chloride injection, the normal acid pH of the solutions is buffered at pH 
6.0  to  6.5,  thus  ensuring  the  anitbiotic’s  activity.  Carbenicillin  should  not  be 
admixed  in  the  same  solution  as  carbenicillin,  Adding  other  drugs,  such  as 
metaraminol bitartrate,  ascorbic acid, or tetracycline hydrochloride,  that have a 
low pH to the intravenous fluid containing the penicillin may lower the pH to a 
point  at  which the penicillin  may be inactivated.  The same can happen if  the 
reconstituted penicillin solution is added to intravenous fluids of high buffering 
capacity that have a pH below 6.0 such as Lactated Ringer’s Injection or protein 
hydrolysates.
In a similar manner, the addition of the reconstituted penicillin to solutions 
in the alkaline range can be deleterious. Dilute sodium bicarbonate solutions are 
sometimes added to 5% distilled water to reduce the incidence of phlebitis, or the 
bicarbonate  ion  may  be  used  for  treating  acidosis.  Studies  have  shown  that 
penicillin present in solution at pH 8.5 retain only 25% of its activity after 6 hours 
and 1% after 24 hours. With higher temperatures or higher pH, the inactivation of 
the antibiotic is accelerated.
The stability  of  the  antibiotic  sodium ampicillin  is  also pH dependent. 
When  reconstituted  sodium  ampicillin  is  added  to  5%  distilled  water  at  the 
concentration  of  30  mg  /  ml,  its  period  of  stability  under  the  prevalent  acid 
conditions is 4 hours. When added to sodium chloride injection, however its loss 
in activity is less that 10% in 8 hours. For this reason sodium chloride injection is 
the intravenous fluid for sodium ampicillin.
Drug stability and compatibility issues in drug delivery (Lawrence A. 
Trissel, 1998):
Drug stability and compatibility are critical elements in the accurate and 
appropriate delivery of the drug therapy to patients. Both the therapeutic adequacy 
of the treatment and the safety and the therapy can be adversely affected by drug 
instability or drug incompatibility.
The  term  instability  is  usually  applied  to  chemical  reactions  that  are 
incessant,  irreversible  and  result,  in  distinctly  different  chemical  entities 
(degradation  products)  that  can  be  both  therapeutically  inactive  and  possibly 
exhibit greater toxicity. 
Incompatibility generally refers to physiochemical  phenomenon such as 
concentration – dependant precipitation and acid base reactions with the product 
of reaction manifested as a change in physical state or protonation – deprotonation 
equilibrium.  When  the  incompatibility  results  in  visible  change(s)  in  color  or 
viscosity,  effervescence  or  the  formation  of  immiscible  liquid  layer  the  term 
physical  incompatibility  or  more  accurately  visual  incompatibility  is  used. 
Expiration  time  shelf  life  (or)  utility  time  restrictions  result  from  the  drug 
instability or incompatibility as well as from other factors such as maintenance of 
sterility. Typically these terms indicate the period for which a minimum of 90% of 
the drug remains intact and available for delivery. Most often, an expiration date 
is applied to the indirect formulation from the manufacture, while a much shorter 
utility  time  is  determined  for  the  drug  when  constituted  and  diluted  for  the 
administration. The term shelf life has been applied to both of these situations.
When  formulating  a  drug  into  a  suitable  parenteral  dosage  form,  a 
manufacturer uses adjuvants or added substances to obtain a stable solution. When 
a drug is added to an intravenous fluid, the conditions of the drug are changed. 
Drugs packed under an inert atmosphere such as nitrogen, because of their ease of 
oxidation, loose this protection and the value of any antioxidant present when they 
are added to the intravenous fluid. The added substances in one injection may not 
be compatible with the drug and the added substances in another when they are 
placed together in intravenous fluid. Placing two injections together in the same 
syringe may accentuate the problems because of the concentrations involved and 
the  difficulty  in  thoroughly  mixing  the  injections,  creating  what  is  called  a 
“layering effect”.
Many injections have special storage requirements such as protection from 
light  or  refrigeration.  Using  these  solution  with  intravenous  fluids,  not 
administering  them immediately,  or  administering  them for  prolonged  periods 
may produce conditions not favorable to the drugs stability.
The primary IV fluid is usually a carbohydrate, electrolyte, or amino acid 
solution.  Carbohydrate  solutions  are  not  usually  a  problem  with  additives; 
although  they  are  acidic,  they  have  negligible  buffer  capacity,  and  additive 
determines  the  pH.  Calcium  and  phosphate  in  TN  (Total  Nutrition)  solution 
require special care in mixing. Lactate, acetate and gluconate present as salts can 
act  as  buffer  and resist  changes  in  pH that  may make  the  additive  insoluble. 
Amino acid–containing IV solutions may degrade acid-labile drugs, bind drugs or 
form  complexes.  No  drug  additives  should  be  mixed  with  fat  emulsion 
(Intralipid).
Drug products must meet stability standards for long-term storage at room 
temperature  under  the  condition  of  relative  humidity.  Drug  instability  in 
pharmaceutical formulations may be detected in some instances by a change in the 
physical appearance, color, taste, odor or texture of the formulation were as in 
other instances chemical changes may occur which are not self-evident and may 
not be ascertained through chemical analysis.
The study of the rate of the chemical change and the way in which it is 
influenced by such factors as the concentration of the drug are reacted, the solvent 
employed, the conditions of temperature and pressure, and the presence of other 
chemical changes in the formulations is termed reaction kinetics.    
In general a kinetic study begins by measuring the concentration of the 
drug being examined at given time intervals under a specific set of conditions 
including temperature, pH, ionic strength, light intensity and drug concentration. 
The measurement of the drug concentration at various time intervals reveals the 
stability or instability of the drug under the specified conditions with the passage 
of time. From this starting point, each of the original conditions may be varied on 
an individual  basis  to  determine  the influence  that  such changes  make  on the 
drug’s stability.  For e.g. The pH of the solution may be changed, whereas the 
temperature, light intensity, and original drug concentration remains as they were 
in the original or baseline experiment.
In addition to the accelerated stability, drug products are also subjected to 
long-term stability  studies  under  the  usual  conditions  of  transport  and storage 
expected during product  distribution.  In conducting these studies,  the different 
climatic  zones,  nationally  and  internationally,  to  which  the  product  may  be 
subjected  must  be  borne  in  mind  and  expected  variances  in  conditions  of 
temperature and humidity included in the study design.
When chemical  degradation  products  are  detected,  the FDA (Food and 
Drug Administration) requires the manufacturer to report their chemical identities, 
including structure, mechanism of formation,  physical and chemical properties, 
procedures  for  isolation  and  purification,  specifications  and  directions  for 
determining at levels expected to be present in the pharmaceutical products, and 
the pharmacological action and biological significance, if any, to their presence.
Stability of Parental products (James C Boylan. et.al, 1995):
A formal stability program is needed to assure that all critical attributes of 
any drug product  are  maintained  through  out  the  shelf  life  of  the  product.  A 
validated  stability-testing  assay  is  essential  to  measure  chemical  or  biological 
activity, and acceptance criteria
Should be established before initiating stability studies. Particular attention 
should be given for developing a detailed protocol for a stability study before 
preparing stability samples, including assays to be performed, storage conditions 
and sampling intervals
In general, expiration dating is based on the estimated time required for 
the active compound to reach Labeled potency at the specified room temperature. 
The  drug  substance  itself  may  be  subjected  to  physical  instability  such  as 
adsorption.  The  stability  program should  include  placing  enough  units  at  the 
specified storage conditions to allow inspection of a statistically valid number of 
units to verify acceptable appearance of the product, such as the development of 
haze and or discrete particulate matter in solution products, as well as to check for 
discoloration or any other physical  attribute  that would result in un acceptable 
pharmaceutical elegance. Formulation pH is often a critical attribute that must be 
monitored during a stability study, since pH may be affected by both by chemical 
reactions  or by interactions  between the formulation  and the container  closure 
system 
Sterile  powder may require special  attention to identify which tests  are 
required to assure adequate physical and chemical stability. The stability of many 
dried  products  is  often  sensitive  to  small  amount  of  residual  water  present, 
requiring  monitoring  of  residual  moisture  by  Karl  Fischer  titration  or  loss  on 
drying.  This is particularly important for protein formulations.
For freeze dried products cake shrinkage with time is  uncommon.  This 
may  be  accompanied  with  discoloration,  increased  reconstitution  time,  or 
crystallization of one or more compounds of the formulation the physical state 
other  drugs-crystalline  or  amorphous-has  an  important  influence  on  stability, 
particularly for cephalosporin’s
Parenteral Dosage Forms And Their Stability Profiles :
Signs of degradations of the specific dosage forms must be observed and 
reported. For some of the dosage forms, this includes the following:
Small  Volume Parenterals :
Strength, appearance, color, particulate matter, dispersibility (suspension), 
pH, sterility, pyrogenicity and closure integrity. 
Large Volume Parenterals :
Strength, appearance, color, particulate matter, pH, volume and extractable 
(when plastic containers are used), sterility, pyrogenicity and closure integrity.
Parenteral Admixtures :
The combination of parenteral dosage forms for administration as a single 
entity  is  called  “admixture”.  Because  of  convenience,  intravenous  fluids  are 
frequently  used  as  vehicles,  or  carriers,  for  other  parenteral  drugs.  The  drug 
placed in solution in another parenteral dosage is the additive.
Numerous studies have been done to determine the extent of admixture 
use.   Studies  at  the  National  Institute  of  Health  (NIH)  and  the  University  of 
Michingan showed that 50 to 70% of the intravenous fluids administered contain 
additives. Other survey showed that the majority of the orders received contained 
1 or 2 additives, and a small percentage required as many as 6 additives to be 
administered in the same intravenous fluid.
Theoretically, the number of possible combination of parenteral drugs in 
intravenous fluids is staggering. A group at the University of Chicago calculated 
that 24 drugs added in groups of 2 to 5% distilled water produced 276 unique 
pairs. In this particular hospital, there was the possibility of using any one of 36 
different intravenous fluids as the vehicle thus brining the number of possibilities 
to over 9000. If the 24 drugs were used in combinations of twos, threes and fours 
when added to 5% distilled water, these combinations produced 11,000 unique 
admixtures.  When varied  with  the  36  different  intravenous  solutions  these  24 
drugs could produce over 396,000 possible combinations. The inclusion of any of 
the other hundreds of parenteral  drugs available with the 24 used in this study 
rapidly increases the number of possibilities. Recognizing the extent of possible 
combinations  is  important  in  seeking  a  reasonable  and  practical  solution  to  a 
problem.
Other  important  factors  in  considering  the  number  of  combinations 
possible include brand variations, drug concentration, added substances, order of 
mixing, and time elapsing prior to administration.
As the number of additives increased, the likelihood of creating conditions 
unfavorable for the stability of one or more of them also increases. Aminophylline 
Injection  added  to  Sodium  chloride  injection  already  containing  vitamin  B 
complex and vitamin C as additives results in an alkaline solution unfavorable to 
the stability of the vitamins.
Complexation  can  occur  between  drugs,  rendering  them  inactive. 
Tetracycline in the presence of calcium ions forms a complex that reduces the 
tetracycline activity.
Parenteral Incompatibility:
The  physical,  chemical  and  therapeutic  problems  that  arise  when 
parenteral  drugs are  combined administered  by injection are called “parenteral 
incompatibility”.  The  tendency  of  practitioners  to  prescribe  several  drugs 
combined and administered together  is  prompted by the convenience and time 
saving  features  of  the  practice,  the  reduction  in  the  number  of  injection’s 
necessary, an attempt to treat several conditions simultaneously, and the ability to 
give the drugs in controlled increments. Although problems have probably existed 
since the acceptance  of  the parenteral  method of administration,  only recently 
have they become a concern to practitioners, owing to the number of increasing 
use of large volume parenteral fluids as vehicles for other drugs.
Large  –volume  fluids  have  their  own  therapeutic  uses;  they  were  not 
necessarily formulated to act as carrier’s or vehicle’s for other drugs. Likewise, 
parenteral  drugs  used  as  additives  were  not  necessarily  formulated  to  remain 
stable  and  active  when  added  to  one  of  a  variety  of  large  –  volume  fluids. 
Nevertheless, current medical practice results in this use for these solutions and 
the potential problem of parenteral incompatibility arises.
The  NCCLVP  (National  Coordinating  Committee  on  Large  volume 
Parenterals) has defined incompatibility as a phenomenon that occurs when one 
drug  is  mixed  with  others  to  produce,  by  physiochemical  means  a  product 
unsuitable for administration to the patient. The patient may not receive the full 
therapeutic effect of the mixture, or toxic decomposition products may result. The 
precipitated incompatibility may irritate the veins or cause occlusion of vessels.
Many hospitals have established pharmacy intravenous additive programs, 
which have centralized the responsibility, increased the uniformity, and improved 
the safety of combining drugs for parenteral administration. Such services have 
been a contributing factor in improving patient care.
Intravenous fluids:
Large volume injections intended to be administer by intravenous infusion 
commonly are called I.V fluids and are included in the group of sterile products 
referred to as large volume parenterals.  These consist of single dose injections 
having a volume of 100mlor more and containing no added substances. Mini type 
infusion containers of 250ml capacity are available with 50ml and 100ml partial 
fills for solution of drugs used in the piggy bag technique. In addition to the IV 
fluids, this group also includes irrigation solutions and solution for dialysis.
Intravenous  solutions  are  sterile  solutions  of  simple  chemicals  such  as 
sugars,  amino acids,  or electrolytes-materials  that  easily can be carried by the 
circulatory system and assimilated.  Prepared with water for injection USP, the 
solutions  are  pyrogen  free,  because  of  the  large  volumes  administered 
intravenously, the absence of particulate matter assumes a significant role in view 
of  possible  biological  hazards  resulting  from  insoluble  particles,  absence  of 
particulate matter or clarity of IV fluids    
Is as important at the time of administration following their manipulation 
in the hospitals as it is at the manufacture of injection.
Limits  of  particulate  matter  occurring  in  IV  fluids  or  large  volume 
injections used for single dose infusion are defined in the USP. Limits also apply 
to  multiple  dose  injections,  mall  volume  injections  prepared  by reconstitution 
from sterile  solids.  The USP defines  particulate  matter  as  extraneous,  mobile, 
undissolved  substances  other  than  gas  bubbles,  unintentionally  present  in 
parenteral solutions.
Intravenous fluids  are  commonly used for  a  serious  of  body condition. 
These include
• Correction of disturbances in electrolyte balance
• Correction of disturbances in body fluids
• The means of providing basic nutrition
• The basis for the practice of providing parenteral nutrition
• Vehicles for other drug substances
In both of the latter two cases it has become common practice to add other 
drugs to certain IV fluids to meet the clinical needs of the patient. Using IV fluids 
as  vehicles  offers  the  advantage  of  convenience,  the  means  of  reducing  the 
irritation  potential  of  the  drug,  and  a  method  for  continuous  drug  therapy. 
However the practice requires that careful considerations be given to the stability 
and compatibility of additives present in the IV fluids serving as the vehicle. This 
approach also demands strict adherence to aseptic techniques in adding the drug 
as well as in the administration of the IV fluids.
Intravenous admixture (Salvatore J Turco. 2000) :
It has been estimated that 40% of all drugs administered in hospitals are 
given in the form of injections, and their use is increasing. Part of this increase in 
parenteral therapy is due to the wider use of intravenous fluids (I.V fluids).
Not  only  to  I.V  fluids  continue  as  the  means  of  fluid  replacement, 
electrolyte balance restoration, and supplementary nutrition, they also are playing 
major roles as vehicles for administration of other drug substances and in total 
parenteral nutrition
The  parenteral  prescription  is  becoming  increasingly  important  in 
hospitals.  Centralized  admixture  program  are  found  in  90%of  the  Nation’s 
hospitals with 300 beds or more in USA. Equipment available for administering 
I.V fluids has become sophisticated and has made possible increased accuracy of 
dosage and led to the development of new concepts and methods of nutrition and 
drug therapy.
New methods of IV drug delivery systems have been introduced and are 
constantly  evolving.  The  introduction  of  patient  controlled  analgesia  is 
commonplace in hospitals. This technology allows the patient with pain to control 
the degree of analgesia.
Packaging of parenteral in the past 5 years also has undergone dramatic 
changes.  The  manufacturers  now  supply  prefilled,  prefrozen,  premixed 
parenterals.  The  pharmaceutical  industry  has  responded  to  the  needs  of 
pharmacists  by  addressing  the  packaging,  labeling,  and  design  requirements 
necessary to facilitate patient care. 
Minimization Of Incompatibilities (Lawrence A . Trissel, 1998):
Although  it  may  be  impossible  to  predict  and  prevent  all  parenteral 
incompatibilities,  practicing  the  following  general  principles  is  helpful  in 
minimizing the difficulties.
 Uses  freshly  prepare  solutions  if  possible;  periodically  observing  the 
running of the intravenous fluid to detect changes in appearance. Discard any 
unused  solution  after  24  hours.  Refrigeration  may  be  requiring  if  it  is 
necessary to prepare admixture in advance. Proper storage temperatures must 
be maintained prior to infusion. Although furosemide (Lasix) does not require 
refrigeration, it is sometimes stored under refrigeration in prefilled syringes to 
reduce the effects of light. This can cause crystallization and should not be 
done.  Cephaloridine  (Loridine)  injections  become  milky  white  during 
refrigeration and should be returned to room temperature prior to use.
 Encourage the use of as few additives as possible in infusion fluids. As 
additives increase, so the number of potential problems. When one concludes 
that vitamin B complex with vitamin C may contain up to 10 drug substances 
in  addition  to  the  pharmaceutical  adjuvant  present,  the  potential  problems 
occurring  becomes  clear.  Mixing  thoroughly  after  each  additive  addition 
prevents concentrated layering effects. 
 Dilution may prevent incompatibility; for e.g.: erythromycin lactobionate 
is  incompatible  with  electrolytes  in  concentrated  form;  however;  it  is 
compatible when properly diluted. It will form a solid gel in a small vial of 
0.9%  sodium  chloride;  in  a  liter  bottle  of  0.9%  sodium  chloride,  it  will 
dissolve completely.
 Become  knowledgeable  about  parenteral  therapy.  The  practitioner  can 
become aware of incompatibilities through the literature.
 Make  physicians  and  others  aware  of  possible  incompatibilities  and 
always be ready to suggest alternate approaches to avoid the difficulties. In 
some instance, compatibilities can be avoided by selecting another route or 
site of administration for one of the drugs involved.
 The preparation of the admixture should be accomplished using aseptic 
techniques in a proper area. The containers of the injections to be used should 
be examined for acceptability in all aspects, such as clarity, absence of cracks 
in the glass, and presence of vacuum if the system requires it.
 Keep a file of available data and add to it from your own experience and 
literature.
 Utilize  available  compatibility  charts.  Although  these  charts  have 
limitations,  the  proper  use of  the  information  can  be  helpful  in  predicting 
incompatibilities. Most charts list only physical incompatibilities, they cannot 
be  used  for  chemical  or  therapeutic  incompatibilities.  The  chart  for  other 
systems can be helpful, but they cannot be depended on categorically to rule 
out  a  problem.  The  same  injections  prepared  by different  companies  may 
differ in pH values. If the brand or source of additive varies from the one used 
in compilation of the chart, the results may differ because different substances 
are used by various companies to prepare the additives,. If the concentration of 
the drug in a specific problem is different from that used in compiling the 
chart the results may also be different. The data in the chart are concentration–
dependent  and  the  concentration  per  unit  volume  is  frequently  specified. 
Charts are updated form time to time; thus the age of the data can influence 
results. 
If the order of mixing is different from the order used in preparing the chart,  
the  results  can  be  different.  Most  charts  specify  a  definite  period  of 
observation, usually 24 hour
 It  is  impossible  to  chart  or  discuss  every  possible  admixture.  Instead, 
principles must be learned and applied; for e.g. no drug should ever be added 
to blood or blood products. According to the charts almost every type additive 
causes an incompatibility when added to protein hydrolysate solutions. Yet it 
is  common  practice  to  combine  several  additives  in  hyperalimentation 
solutions. Penicillin form potentially allergenic conjugates with proteinaceous 
materials.  Therefore it  is  not  advisable to  add them to protein hydrolysate 
solution.  Other  general  principles  to  remember  are  that  penicillins  are 
inactivated  at  either  low or  high  pH values;  sympathomimetic  amines  are 
specially sensitive when added to intravenous fluids; and therapeutic large–
volume solutions such as sodium bicarbonate, urea, mannitol, dextran, and L- 
arginine should never contain additives.
ICH GUIDELINES ON STABILITY: (ICH guidelines, 1993) :
One of the constants  in our industry is  the continuing need to develop 
information  about  the  stability  of  active  pharmaceutical  ingredients  and  drug 
products we work with.  The need to know the stability of materials that are in 
development, that are in the clinic and that are being manufactured commercially 
has resulted in a number of regulatory documents describing the procedure that 
should be used to generate the required stability information.
The  International  Conference  on  Harmonization  (ICH)  has  published 
extensively on the subject of stability.  As a part of the ICH, FDA has adopted the 
ICH guidelines on the conduct of stability studies.
The first ICH guideline on stability reached step 4 of the ICH process and 
was recommended for adoption in October 1993. The guideline was revised in 
1999  and  the  revised  guideline  was  recommended  for  adoption  in  November 
2000.
These Guidelines are:
• Stability Testing: photo stability testing of new drug substances 
and products Q1B (1996)
• Stability  Testing  for  New dosage  forms:  Annex  to  the  ICH 
Tripartite  guideline  on  stability  testing  for  new  drugs  and  products  Q1C 
(1996)
• Bracketing and matrixing designs for stability testing of new 
drug substances and products Q1D (2002)
• Evaluation for stability data Q1E (2003)
• Stability data package for registration applications in climatic 
zones 3 and 4 Q1F (2003)
The  purpose  of  a  stability  study  is  to  establish,  based  on  testing  a 
minimum of three batches of the drug substance or product,  a retest  period or 
shelf  life  and  label  storage  instructions,  applicable  to  all  future  batches 
manufactured and packaged under similar circumstances.
Guideline  Q1A and the first  revision  established the  general  case for  stability 
studies as:
Storage condition Temperature Relative humidity
Long term storage condition 25ºc ±2ºc 60% RH ±5% RH
Intermediate Storage 
condition
30ºc ± 2ºc 65% RH ±5% RH
Accelerated storage 
condition
40ºc ± 2ºc 75% RH ±5% RH
The intermediate storage condition has been changed to:
30ºc ± 2ºc/ 65% RH ±5% RH for drug substances and drug products. The 
stability of a product depends not only on the nature of the packaging material but 
also  on  factors  such  as  conditions  during  packaging,  pack  design  and  pack 
geometry,  including head space.  Over protective packaging adds to the cost of 
packaging;  therefore  it  is  important  to  determine  what  packaging  is  really 
necessary in each case..
DRUG PRODUCT
General
The design of the stability programme for the finished product should be 
based on the knowledge of the behavior and properties of the drug substance and 
the  experience  gained from clinical  formulation  studies  and from the  stability 
studies on the drug substance.  The likely changes on storage and the rationale for 
the selection of product variables to include in the testing programme should be 
stated.
Selection of Batches
Stability  information  from  accelerated  and  long  term  testing  is  to  be 
provided  on  three  batches  of  the  same  formulation  and  dosage  form  in  the 
containers and closure proposed for marketing.  Two of the three batches should 
be at least pilot scale.  The third batch may be smaller (e.g., 25,000 to 50, 0000 
tablets  or  capsules  for solid  oral  dosage forms).  The long term testing should 
cover at least 12 months duration at the time of submission.  The manufacturing 
process to be used should meaningfully simulate that which would be applied to 
large-scale  batches  for  marketing.   The process  should provide product  of  the 
same quality intended for marketing, and meeting the same quality specification 
as to be applied for release of material.
Data  on  laboratory  scale  batches  is  not  acceptable  as  primary  stability 
information.  Data on associated formulations or packaging may be submitted as 
supportive  information.   The  first  three  production  batches  manufactured  post 
approval, if not submitted in the original registration application, should be placed 
on accelerated and long term stability studies using the same stability protocols as 
in the approved drug application. 
Test Procedures and Test Criteria
The  testing  should  cover  those  features  susceptible  to  change  during 
storage  and  likely  to  influence  quality,  safety  and  efficacy.   Analytical  test 
procedures should be fully validated and the assays should be stability indicating. 
The need for the extent  of replication will  depend on the results  of validation 
studies.
The  range  of  testing  should  cover  not  only  chemical  and  biological 
stability  but  also  loss  of  preservative,  physical  properties  and  characteristics, 
organoleptic  properties  and  where  required,  microbiological  attributes. 
Preservative efficacy testing and assays on stored samples should be carried out to 
determine the content and efficacy of antimicrobial preservatives. 
Specifications
Limits of acceptance should relate to the release limits (where applicable), 
to be derived from consideration of all the available stability information.  The 
shelf life specification could allow acceptable and justifiable derivations from the 
release specification based on the stability evaluation and the changes observed on 
storage.  It will need to include specific upper limits for degradation products, the 
justification for which should be influenced by the levels observed in material 
used in pre-clinical studies and clinical trials.
Storage Test Conditions
The length of the studies and the storage conditions should be sufficient to 
cover  storage,  shipment  and subsequent  use (e.g.,  reconstitution  or  dilution  as 
recommended in the labeling).  An assurance that long term testing will continue 
to cover the expected shelf life should be provided.
Other storage conditions are allowable if  justified.   Heat sensitive drug 
products should be stored under an alternative low temperature condition, which 
will  eventually become the designated long-term storage temperature.   Special 
consideration may need to be given to products, which change physically or even 
chemically at lower storage conditions.  Where a lower temperature condition is 
used, the six months accelerated testing should be carried out at a temperature at 
least  15ºC  above  its  designated  long  term storage  temperature  (together  with 
appropriate relative humidity conditions for that temperature).  For example for a 
product to be stored long term under refrigerated conditions, accelerated testing 
should  be  conducted  at  25ºC  ±  2ºC  /  60  percent  RH ±  5  percent  RH.   The 
designated  long  term  testing  conditions  will  be  reflected  in  the  labeling  and 
expiration date.
Storage under conditions of high relative humidity applies particularly to 
solid dosage forms.  For products such as solutions, suspensions etc., contained in 
packs  designed  to  provide  a  permanent  barrier  to  water  loss,  specific  storage 
under conditions of high relative humidity is not necessary but the same range of 
temperatures should be applied.  Low relative humidity (e.g. 10-20 percent RH) 
can adversely affect products packed in semi-permeable containers (e.g. solutions 
in  plastic  bags,  nose  drops  in  small  plastic  containers  etc)  and  consideration 
should be given to appropriate testing under such conditions.
Conditions Minimum time periodat submission
Long term testing 25ºC ± 2ºC / 60% RH ± 5% 12 Months
Accelerated testing 40ºC ± 2ºC / 75% RH ± 5% 6 Months
Where  significant  change  occurs  due  to  accelerated  testing,  additional 
testing at an intermediate condition e.g.
30ºC ± 2ºC / 60% RH ± 5% RH should be conducted.  
Significant change at the accelerated condition is defined as:
1. A 5 percent potency loss from the initial value of a batch.
2. Any specified degradant exceeding its specification limit.
3. The product exceeding its pH limits.
4. Dissolution exceeding the specification limits for 12 capsules or tablets.
5. Failure to meet specifications for appearance and physical properties e.g., 
color,  phase  separation,  resuspendibility,  delivery  per  actuation,  caking, 
hardness etc.
Should significant  change occur  at  40ºC/75 percent  RH then the initial 
registration  application  should  include  a  minimum of  6  months  data  from an 
ongoing  one  year  study  at  30ºC/60  percent  RH;  the  same  significant  change 
criteria shall then apply.
The long term testing will be continued for a sufficient time beyond 12 
months to cover shelf life at appropriate test periods.
Testing Frequency
Frequency  of  testing  should  be  sufficient  to  establish  the  stability 
characteristics of the drug product.  Testing will normally be every three months 
over the first year, every six months over the second year and then annually.
Evaluation
A  systematic  approach  should  be  adopted  in  the  presentation  and 
evaluation of the stability information which should cover all necessary physical, 
chemical, biological, microbiological quality characteristics, including particular 
properties of the dosage form.
The  design  of  the  stability  study  is  to  establish,  based  on  testing  a 
minimum of  three  batches  of  the  drug product,  a  shelf  life  and label  storage 
instructions applicable to all future batches of the dosage from manufactured and 
packed under similar circumstances.
Where the data shows so little degradation and so little variability that it is 
apparent from looking at the data that the requested shelf life will be granted, it is 
normally unnecessary to  go through the  formal  statistical  analysis  but  only to 
provide a justification for the omission.
Any evaluation should consider not only the assay, but also the levels of 
degradation  products  and  appropriate  attributes.   Where  appropriate,  attention 
should be paid to reviewing the adequacy of the mass balance, different stability 
and degradation performance.
Statements/Labeling
A storage  temperature  range may be  used  in  accordance  with  relevant 
national/regional  requirements.   The  range  should  be  based  on  the  stability 
evaluation of the drug product.  Where applicable, specific requirements should 
be stated particularly for drug products that cannot tolerate freezing.  There should 
be a direct  linkage between the label  statement  and the demonstrated stability 
characteristics of the drug product.
CLASSIFICATION OF STABILITY STUDIES:
Stability studies can be broadly classified as follows:
• Accelerated studies
• Long term studies
ACCELERATED STUDIES:
It is generally conducted on actual formulations for several weeks under 
accelerated conditions of temperature, humidity or light.  The primary objective of 
these studies is to obtain an early reading on whether a given active ingredient or 
formulation is likely to be sufficiently stable to deserve detailed exploration.
In performing these studies, an active ingredient or a formulation can be 
subjected to  much higher  temperatures,  humidity or  light  conditions  than it  is 
likely  to  be  subjected  to  under  normal  transportation,  storage  and  usage 
conditions.   For  example,  an active  ingredient  may be subjected to  increasing 
temperatures until decomposition is detected
LONG TERM STABILITY:
Formulations  are  designed  to  maintain  or  enhance  the  stability  of  the 
active ingredients while allowing optimal delivery in the human body.  The design 
is  based  on  the  physicochemical  properties  of  the  active  ingredient  and  its 
compatibility  with  the  excipients.   Many  approaches  are  used  to  stabilize  or 
protect  formulations  including  lyophilization,  microencapsulation,  control  of 
surface  area,  addition  of  chelating  agents,  preservatives,  and  antioxidants, 
physical separation of incompatible ingredients, coatings and opaque coverings.
The stabilization of a dosage form-container combination is extrinsic to 
the stability of the dosage form.  The container is an integral part of products such 
as topical and parenteral.
STORAGE CONDITIONS:
An important part of stability evaluation is the determination of the effects 
of environmental conditions on the product.  The factors commonly tested are 
heat, humidity, light and air.  Data obtained from these studies form the basis for 
the establishment of an expiration date.  Temperature can vary from one place to 
other therefore; it is best to relate laboratory storage of stability samples to actual 
market conditions.
Storage conditions stipulated in individual monographs are defined as:
• Cold - Any temperature not exceeding 8ºC.
• Cool - Any temperature between 8 and 15ºC.
• Room temperature – Between 15 and 30ºC.
• Warm - Any temperature between 30 and 40ºC.
• Excessive heat - Any temperature above 40ºC
The climatic conditions around the world can be classified into the following four 
categories:
I. Temperate climate (20ºC, 42% RH)
II. Subtropical climate (21.6ºC, 52% RH)
III. Hot, dry climate (30ºC, 40% RH)
IV. Hot,  humid climate (30ºC, 70% RH)
There  are  three  bases  upon  which  pharmacists  are  able  to  recognize, 
predict  and avoid instability in parenteral  solutions  (David.  W. Newton, 1978) 
they are: 
1. Professional judgment derived from direct experience.
2. A  competent  understanding  of  physicochemical  principles  with  particular 
emphasis on common reactive and labile groups.
3. Reference to pertinent published information.
STABILITY INDICATING METHODS: (Jens T. Cartensen, 
2005) :
A stability indicating method is an analytical procedure that is capable of 
discriminating between the major active (intact) pharmaceutical ingredients (API) 
from any degradation (decomposition) product(s) formed under defined storage 
conditions during the stability evaluation period.
FDA  defines  stability  indicating  methods  as  a  quantitative  analytical 
methods  that  are  based  on the  characteristic  structural,  chemical  or  biological 
properties of each active ingredient of a drug product and that will distinguish 
each active ingredient from its degradation products so that the active ingredient 
content can be accurately measured.
Developing  a  stability  indicating  assay  requires  consideration  of  three 
aspects of the method:
1. Obtaining a representative sample
2. Choosing the separation technique and
3. Selecting the detector.
1. Obtaining a representative sample:
To obtain samples for developing stability indicating assays the pure drug 
substance  were  placed  under  stress  intentionally.  This  process  is  often  called 
forced degradation or purposeful degradation. The drug may be subjected to acid, 
base, heat, light or oxidation for stress degradation. Usually, the goal is to degrade 
the parent drug by 10-20% or so. Degradation much greater than 10-20% could 
result in secondary degradants that will complicate the development process.
2. Choosing the separation technique:
a. Chromatographic methods:
A  large  number  of  stability  indicating  methods  entail  some  form  of 
chromatography:  thin-layer,  gas  (GLC),  liquid  (HPLC),  or  supercritical  fluid 
(SFC).  Of these methods HPLC has found the greatest application.
i. HPLC
In  this  method,  the  samples  are  generated  in  aqueous  solutions.  The 
polarity of the degraded samples can vary widely; for example, when a non-polar 
drug is degraded into smaller polar components, then gradient elution is employed 
for sample screening.
ii. HPTLC
In this method, the drug can be effectively separated from its degradation 
products. All the peaks of degradation products can be well resolved from the 
standard drug with significant difference in R(f) values.
b. Spectrophotometric method:
Derivative spectrophotometry presents greater selectivity than the normal 
technique and overcomes the problem of resolving spectral overlap in the analysis 
of  a  multicomponent  system.  A  characteristic  of  this  technique  is  that  the 
differentiation discriminates against broad bands, emphasizing sharper features to 
an extent that they increase with increasing derivative order. 
Selectivity can be improved through chromatographic separations or by 
reaction of an appropriate functional group.  For example reactions that produce 
colored  product  are  measured  in  the  visible  region  of  the  spectrum.   Other 
reactions increase conjugation to permit measurement in the UV region.
IR analysis is primarily used for identification of decomposition products 
and has found very few quantitative applications in stability evaluations.  Nuclear 
magnetic  resonance  is  finding increasing number  of applications  since it  offer 
sspecificity along with simplicity of operation.  Mass spectrometry in combination 
with GC or HPLC has been found useful in some cases for monitoring impurities 
in pharmaceutical compounds.
3. Selecting the detector:
The detector  should  determine  the  sample  components  within  atleast  a 
1000 fold concentration range from 100% to 0.1-0.05% of the parent drug.
DRUG PROFILE
CIPROFLOXACIN HYDROCHLORIDE (AHFS drug information, 2004)
Structure: 
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Figure-1 Structure of Ciprofloxacin hydrochloride
MECHANISM OF ACTION :
Ciprofloxacin is bactericidal and acts by inhibiting the A sub unit of DNA 
gyrase (topoisomerase) which is essential in the reproduction of bacterial DNA. 
PHARMACOKINETICS :
Ciprofloxacin is rapidly and well absorbed from gastro intestinal tract. Its 
bioavailability  is  about 70%, Protein binding ranges from 20-40% and plasma 
half-life  is  about  3.5  hours.  It  is  widely  distributed  in  the  body  and  tissue 
penetration is generally good. It is eliminated by urine excretion but non renal 
clearance may account for about a third of elimination 
DRUG INTERACTION :
Administration  of  ciprofloxacin  with theophylline  may lead to  elevated 
serum concentration of theophylline and prolongation of its elimination half-life. 
Ciprofloxacin have also been shown to interfere with the metabolism of 
caffeine.  Concurrent  administration  of  ciprofloxacin  with  antacids  containing 
magnesium, aluminium, or calcium with sucralfate or divalent or trivalent cat ions 
such  as  iron  may  substantially  interfere  with  the  absorption  of  ciprofloxacin 
resulting in serum and urine levels considerably lower than desired.
DOSAGE :
Adult  oral  dose  250-750mg twice  daily  depending on the  severity  and 
nature of the infection. Intravenous dose is 100-400mg twice daily.  Single oral 
dose  of  750mg  is  suggested  for  surgical  infection  prophylaxis,  given  60-90 
minutes before the procedure.
METRONIDAZOLE (AHFS drug information,  
2004)
Structure:
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Figure-2 Structure of Metronidazole
ADMINISTRATION AND DOSAGE:
It  is  commonly  used  orally.  Occasionally  it  is  used  intra  vaginally  in 
hospitalized patients. It is used mainly as IV bolus along with other antibiotics.
Table: 1
Metronidazole dosage guidelines:
Infection Route
Unit 
dose
Frequency Duration
Daily 
dose
Anaerobic infections 
( lower respiratory 
tract and 
endocardium)
IV 15mg/kg 6 hrs 7-10 days < 4 g
Prophylaxis  
(hepatic and renal 
diseases)
IV 15mg/kg 30-60 mins
Before 6 
hrs
-
COMPATIBILY STUDIES :
Metronidazole  is  compatible  with  several  cephalosporins  in  that 
cefamandole  nafate,  cefazolin  sodium,  cefatoxime  sodium,  ceftazidime, 
cefriaxone.  It  is  also  compatible  with  ciprofloxacin  and  gentamicin.  It  is 
incompatible with amino acids.
STABILITY :
Reconstituted IV solutions are stable for 6 hrs, when stored 
below 26ºC in room temperature. Use diluted and neutralized IV 
solutions within 24 hrs. Store ready to use solution at 15ºC to 30ºC, 
protected from light. Once further diluted in infusion solution and 
neutralized, the solution should be used before 24 hrs. Ready to use 
metronidazole products indicate that these may be refrigerated but 
that crystals may form. The crystal redissolves on warming to room 
temperature. Prolonged exposure to light will cause a darkening of 
product. Direct sunlight should be avoided.
CLINICAL USES : 
• It is used in the treatment of genital infections with T.vaginalis in both female 
and males in high percentage of cases.
• It is an effective amoebicide and has become the agent of choice for treatment 
of all symptomatic forms of amoebicide.
• Metronidazole has become the drug of choice for the treatment of giardiasis.
• It is extremely used for the treatment of serious infections due to susceptible 
anaerobic bacteria including Bacteriodes, Clostridium, etc.
REVIEW OF LITERATURE
 Falagas ME. et.al, (2007) studied the use of fluoroquinolones for the 
treatment  of  intra-abdominal  surgical  infections  and  reported  that,  in  six 
prospective non-randomized clinical studies of patients with intra-abdominal 
infections,  the  clinical  success  achieved  with  the  use  of  fluoroquinolones 
ranged from 77% to 94%.  They concluded fluoroquinolones to be an effective 
and relatively safe option for the treatment of patients with intra-abdominal 
infections.
 Motwani  SK.  et,al,  (2007) validated  a  stability-indicating  HPTLC 
method for the densitometric determination of moxifloxacin using precoated 
silica gel 60 F254 as stationary phase, n- propanol – ethanol – 6M ammonia 
solution  (4:1:2,  v/v/v)  as  mobile  phase  and  detection  at  298nm.  Stability 
studies were performed by acid and alkali hydrolysis, oxidation, dry heat, wet 
heat treatment and photo degradation. As the method could effectively separate 
the drug from its  degradation products, it  could be employed as a stability- 
indicating method.
 Fernandez-Varon  E.  et.al,  (2006) studied  the  stability  of 
moxifloxacin  injection  in  peritoneal  dialysis  solution  bags  (  Dianeal  PD1 
1.36% and Dianeal PD1 3.86% were two glucose concentrations) by HPLC 
method and reported that  the mean moxifloxacin concentration in the Dianeal 
PD1 1.36% solution remained ≥ 90% of the initial concentration for 14 days at 
4 °C,  7 days  at  25 °C  and  3 days  at  37 °C.  For  Dianeal  PD1  3·86% 
moxifloxacin concentrations remained ≥ 90% for 14 days  at  4 °C, 3 days  at 
25 °C and 12 h at 37 °C.
 Matthaiou DK. et.al, (2006) studied the comparative clinical trials of 
ciprofloxacin/metronidazole  versus  broad-spectrum β-lactam based regimens 
in  the  treatment  of  intra-abdominal  infections  and  concluded  that  the 
ciprofloxacin/metronidazole  combination  may be superior  to  β-lactam-based 
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therapeutic regimens in the treatment of intra-abdominal infections with regard 
to cure of infections.
 Jan  Krzek.  et.al,  (2005)  developed  a  HPTLC  method  with 
densitometric detection for identification and quantification of ciprofloxacin, 
by  using  pre-coated  silica  gel  60  F254 as  stationary  phase  and  chloroform-
methanol-25% ammonia  (43+43+14 ,v/v/v)  as  mobile  phase.  The  degraded 
products of Ciprofloxacin in pharmaceutical  preparations were identified by 
different Rf values. 
 Werk  R.  et.al,  (2005) studied  the  effect  of  combination  of 
ciprofloxacin with metronidazole for the treatment of mixed aerobic/anaerobic 
infections and concluded that metronidazole in combination with ciprofloxacin 
was slightly more  potent  against  the tested  Clostridia than ciprofloxacin  or 
metronidazole alone.
 Madan  AK.  et.al,  (2004) studied  the  use  of  ciprofloxacin  in  the 
treatment  of  hospitalized  patients  with  intra-abdominal  infections  and  after 
clinical  trials  they  concluded  that  the  combination  of  ciprofloxacin  plus 
metronidazole was an effective and safe regimen for the treatment  of intra-
abdominal infections.
 Voges M. et.al, (2004) studied the stability of gentamicin, tobramycin, 
netilmicin, vancomycin, cefazolin, unfractionated heparin and low molecular 
weight heparin when added to four different peritoneal dialysis solutions (PD) 
solutions  (Extraneal,  Physioneal,  Nutrineal,  and Dianeal)  in  new, non PVC 
flex-containers. The study was carried out at two different temperatures (25°C 
and 37°C). 
 Yeung  SM.  et.al,  (2004) studied  the  pharmacokinetics  of  oral 
Ciprofloxacin in continuous cycling peritoneal dialysis (CCPD) patients. The 
concentration  of  Ciprofloxacin  in  blood  samples  was  analyzed  by  HPLC 
method and also by microbiological assay.  They finally concluded that oral 
administration of 750mg Ciprofloxacin in every 12 hours for CCPD patients 
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might be useful for empirical gram-negative coverage of CCPD peritonitis and 
for and for treatment of documented peritonitis caused by E.coli or Klebsiella 
species.   
 Vega  E.  et.al,  (2001)  studied  the  compatability  of  ciprofloxacin-
metronidazole admixture by first-derivative spectrophotometry using the zero-
crossing  technique  of  measurement  and  studied  the  effect  of  light  on  the 
admixture and concluded that the admixture was proved to be photolabile.
 Vega  E.  et.al,  (1999) validated  a  reverse-phase  LC  method  for 
quantitative  analysis  of  intravenous  admixtures  of  ciprofloxacin  and 
metronidazole.
 Bailie  GR.  et.al,  (1995) studied  the  stability  of  drug  additives  to 
peritoneal  dialysate  and reported that most  beta-lactams were stable  for 1-2 
weeks  in  a  refrigerator  and  for  several  days  at  room  temperature. 
Aminoglycosides were stable for 1-2 days at room temperature. Glycopeptides 
were stable for several weeks in refrigerator or at room temperature. Prolonged 
storage at room temperature resulted in instability of cefotaxime, ceftazidime, 
cefriaxone and miconazole.  They also added that additives should be made as 
close as possible to the time of the exchange or additives should be stored 
refrigerated, then warmed prior to use.
 Kane MP. et.al, (1994) studied the stability of ciprofloxacin injection 
in peritoneal dialysis solutions using high-performance liquid chromatography 
at 4,25 and 37°C and concluded that in peritoneal dialysis solutions containing 
1.5% and 4.25% dextrose, ciprofloxacin remained stable for 2 weeks at 4°C,for 
1 week at 25°C and for 2 days at 37°C. 
 Kelly  A  et  al  (2005) studied  the  stability  and  compatibility  of 
levofloxacin  and  metronidazole  during  simultaneous  and  actual  Y-site 
administration  and  reported  that  admixtures  of  levofloxacin  ready  to  use 
infusion  solution  (5mg/ml)  were  visually  and  chemically  compatible  at 
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approximately  23ºC for  up  to3  hours  during  simulated  and  actual  infusion 
through a Y-site. 
 Mawhinney WM. et.al, (1992) studied the stability of ciprofloxacin in 
peritoneal dialysis solution at 4, 20 and 37 degrees C. Samples withdrawn at 
different  time  intervals  were  analysed  by  high  performance  liquid 
chromatography  and  also  by  microbiological  assay  using  Pseudomonas 
aeruginosa. The net percentage of change in ciprofloxacin concentration was 
0.76% after  storage at  4 degree C, 1.02% after storage at  20 degree C and 
0.75% after storage at 37 degree C. 
 Goodwin SD. et.al, (1991) studied the compatability of ciprofloxacin 
injection  with  selected  drugs  and  solutions  by  high  performance  liquid 
chromatography  and  concluded  that  ciprofloxacin  injection  was  compatible 
with  gentamicin,  metronidazole,  and  tobramycin  and  incompatible  with 
aminophylline and clindamycin. The compatability of ciprofloxcacin- amikacin 
admixtures depended on the intravenous solution and storage temperature.
 McCormick. et.al, (1987) studied the effect of peritoneal dialysis fluid 
and  pH  on  bactericidal  activity  of  ciprofloxacin  and  concluded  that  the 
bactericidal  activity  of  ciprofloxacin  is  not  affected  by  pH  or  medium 
(peritoneal dialysis fluid).
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EXPERIMENTAL WORK
INSTRUMENTS AND APPARATUS :
UV Spectrophotometer : Jasco V530
HPTLC : Camag
Refrigerator : Kelvinator
B.O.D Incubator : Technico 
Incubator : Hybrid
Hot air oven : Chemie
Autoclave : Kailash
Horizontal laminar air flow : Serwell instruments
Analytical Balance : Dhona, 200d
Non absorbent cotton : Ramaraju surgicals
Inoculating loop : Hi-media
Pipette (1,5 & 10ml) : Borosil.
Test tubes : Borosil
Standard Flask (10, 100ml) : Borosil 
Sterile swabs : Hi-media
HPTLC plates : Merck
Petri dishes : Borosil
Micropipettes (20-200µl) : Ebrapipette
Micropipettes (50-100µl) : Varipipette 
Microtips : Tarson
Cultural tubes (20ml) : Borosilicate type-2 Borosil
Mueller Hinton Agar media : Hi-media.
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CHEMICALS USED:
Ciprofloxacin injection (2mg/ml) : Cipla 
Metronidazole injection (0.5% v/v) : Nirlife Health Care.
Water for injection : Core Health Care.
Peritoneal dialysis fluid :  Parenteral Drugs (India) Ltd
Chloroform : Qualigens Fine Chemicals
Methanol : Qualigens Fine Chemicals
25% Ammonia : S D Fine Chem. Limited
METHODOLOGY:
CALIBRATION  GRAPH  OF  CIPROFLOXACIN  I.V  USING  FIRST 
DERIVATIVE UV SPECTROPHOTOMETRIC METHOD: (E.Vega.  et.al, 
2001)
a) PREPARATION OF STOCK SOLUTION: 
From 2mg/ml of Ciprofloxacin I.V infusion 5 ml was taken and 
was made up to 100ml with sterile water to get a concentration of 100 
µg/ml of Ciprofloxacin.
b) PROCEDURE:
From the above solution 0.2, 0.4, 0.6, 0.8 and 1.0 ml was pipetted 
and made upto10ml with sterile water to get concentrations of 2, 4, 6, 8 
and 10 µg/ml respectively. The UV spectra and first derivative spectra 
of the above samples were taken and absorbance was measured at 263 
nm.
PROTOCOL FOR THE STABILITY STUDY OF CIPROFLOXACIN I.V  AT 
THREE DIFFERENT TEMPERATURES:
This study was carried out to determine the stability of 
Ciprofloxacin I.V at different temperature conditions of storage, i.e. 
refrigeration (5ºC), room temperature (25ºC) and at 45ºC.  The 
parameters evaluated were changes in physical stability i.e. changes in 
pH, clarity and color. The chemical stability of ciprofloxacin was 
determined using stability indicating first derivative UV 
spectrophotometric method for quantification.
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PROCEDURE:
2mg/ml Ciprofloxacin I.V infusion bottles were marked as 
refrigeration (5ºC), room temperature (25ºC) and 45ºC for 
identification and were kept at different storage conditions.  
From the above samples serial dilutions were made with sterile 
water to get 8 µg/ml concentrations and absorbance was measured at 
263nm. The above procedure was repeated for 5 days with samples 
withdrawn from solutions kept at 5ºC, 25ºC and 45ºC at various time 
intervals of 0min, 1hrs, 2hrs, 4hrs, 6hrs, 24hrs, 72hrs, and 120hrs 
respectively. The pH and clarity were also noted.  The results obtained 
were observed and recorded.
CALIBRATION GRAPH OF METRONIDAZOLE I.V USING 
FIRST DERIVATIVE UV SPECTROPHOTOMETRIC 
METHOD: (E.Vega. et.al, 2001)
a) PREPARATION OF STOCK SOLUTION:
From 5mg/ml of Metronidazole I.V infusion 2ml was taken and 
was made up to 100 ml with sterile water to get a concentration of 100 
µg/ml of Metronidazole.
b) PROCEDURE:
From the above solution 0.2, 0.4, 0.6, 0.8, 1.0 ml was pipetted and 
was made upto10ml with sterile water to get concentrations of 2, 4, 6, 8 
and 10 µg/ml respectively. The UV spectra and first derivative spectra 
of the above samples were taken and the absorbance was measured at 
299 nm. 
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PROTOCOL FOR THE STABILITY STUDY OF 
METRONIDAZOLE I.V AT THREE DIFFERENT 
TEMPERATURES: 
This study was carried out to determine the stability of 
Metronidazole I.V at different temperature conditions of storage, i.e. 
refrigeration (5ºC), 25ºC and at 45ºC.  The parameters evaluated were 
changes in physical stability i.e. changes in pH, clarity and color. The 
chemical stability of Metronidazole was determined using stability 
indicating first derivative UV spectrophotometric method for 
quantification.
PROCEDURE:
5mg/ml of Metronidazole infusions were marked as refrigeration 
(5ºC), room temperature (25ºC) and 45ºC for identification and were 
kept at different storage conditions.  
From the above samples serial dilution was done with sterile 
water to get 8µg/ml concentration and absorbance was measured at 
299nm. The above procedure was repeated for 5 days with samples 
withdrawn from vials kept at 5ºC, 25ºC and 45ºC at various time 
intervals of 0min, 1hrs, 2hrs, 4hrs, 6hrs, 24hrs, 72hrs, and 120hrs 
respectively. The pH and clarity were also noted.  The results obtained 
were observed and recorded.
CALIBRATION  GRAPH  OF  CIPROFLOXACIN-METRONIDAZOLE  I.V 
ADMIXTURE  (BY  SIMULTANEOUS  UV  SPECTROPHOTOMETRIC 
METHOD):
The ratio of 1: 2.5 (Ciprofloxacin: Metronidazole) was used, 
because the same ratio was used during admixture of two drugs in 
clinical practice. Five different concentration mixtures of same ratio 
were prepared (1: 2.5, 2: 5, 3: 7.5, 4: 10, 5: 12.5) and used for 
calibration graph.
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PROCEDURE:
From the 2mg/ml of Ciprofloxacin I.V infusion and 5mg/ml of 
Metronidazole infusion aliquot dilutions were made in the ratio of 1: 
2.5 to get 1, 2, 3, 4 and 5µg/ml concentration of Ciprofloxacin and 2.5, 
5.0, 7.5, 10 and 12.5µg/ml concentration of Metronidazole respectively. 
The UV spectra and first derivative spectra of the above 
solutions were taken and the absorbance was measured at 263 nm for 
Ciprofloxacin and 299 nm for Metronidazole and calibration graph 
were plotted. 
PROTOCOL FOR STABILITY STUDY OF CIPROFLOXACIN- 
METRONIDAZOLE I.V ADMIXTURE AT THREE 
DIFFERENT TEMPERATURES (BY SIMULTANEOUS UV 
SPECTROPHOTOMETRIC METHOD):
This study was carried out to determine the stability of 
Ciprofloxacin-Metronidazole I.V admixture at different temperature 
conditions of storage, i.e. refrigeration (5ºC), 25ºC and at 45ºC.  The 
parameters evaluated were changes in physical stability i.e. changes in 
pH, clarity and color. The chemical stability of ciprofloxacin and 
metronidazole were determined from the calibnration graph prepared 
earlier.
 2mg/ml of Ciprofloxacin I.V infusion and 5mg/ml of 
Metronidazole I.V infusion solutions were mixed in the ratio of 1: 2.5 
and were marked as refrigeration (5ºC), room temperature (25ºC) and 
45ºC for identification and were kept at different storage conditions.  
PROCEDURE:
From the samples at different temperatures aliquot dilutions 
were made to get a concentration of 4 µg/ml of Ciprofloxacin and 10 
µg/ml of Metronidazole (ratio 1: 2.5). The UV spectra and first 
derivative spectra of the solution were taken and the absorbance was 
measured at 263nm for Ciprofloxacin and at 299 nm for Metronidazole 
respectively. The above procedure was repeated for 5 days with 
samples withdrawn from vials kept at 5ºC, 25ºC and 45ºC at various 
time intervals of 0min, 1hrs, 2hrs, 4hrs, 6hrs, 24hrs, 72hrs, and 120hrs 
respectively. The parameters evaluated were changes in physical 
stability i.e. changes in pH and clarity were also noted.  The results 
obtained were observed and recorded.
CALIBRATION GRAPH FOR CIPROFLOXACIN I.V IN PERITONEAL 
DIALYSIS SOLUTION USING HPTLC METHOD: (Jan Krzek. et.al, 2005)
a) PREPARATION OF STOCK SOLUTION :
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From 2mg/ml of Ciprofloxacin I.V infusion 2 ml was taken and 
was made up to 10 ml with peritoneal dialysis solution to get a 
concentration of 400µg /ml. From this solution 1 ml was taken and 
made up to 10 ml with peritoneal solution to give 40µg/ml. 
b) PROCEDURE :
From the above drug solution 0.5µl, 1.0µl, 1.5µl, 2.0µl, 2.5µl with 
corresponding concentrations of 0.02, 0.04, 0.06, 0.08 and 0.1 µg/spot 
were spotted in HPTLC plates of size 10 × 10 cm.  The spots were dried 
and developed using chloroform: methanol: 25% ammonia (4.3:4.3:1.4) 
as solvent system. Peak areas were measured at 277nm.
HPTLC CONDITIONS :
Stationary phase : Silica gel 60F254
Mobile phase : Chloroform: methanol: 25% ammonia   (4.3: 4.3:1.4)
UV detector : 277nm
Injector : Linomat injector
Scanner : CAMAG Scanner
Method : Ascending chromatography
Calibration range : 0.02 to 0.1µg/spot
PROTOCOL  FOR  STABILITY  STUDY  OF  CIPROFLOXACIN  I.V  IN 
PERITONEAL  DIALYSIS  SOLUTION  AT  THREE  DIFFERENT 
TEMPERATURES (Quantification by HPTLC method)
This study was carried out to determine the stability of 
Ciprofloxacin in peritoneal dialysis solution at different temperature 
conditions of storage, i.e. refrigeration (5ºC), 25ºC and at 45ºC.  The 
parameters evaluated were changes in physical stability i.e. changes in 
pH, clarity and color. The chemical stability of Ciprofloxacin was 
determined from the calibration graph prepared earlier.
From 2mg/ml of Ciprofloxacin I.V infusion 2ml was taken and 
made up to 10ml with peritoneal dialysis solution to get a concentration 
of 400µg /ml  and were marked as 45ºC, 25ºC and 5ºC for 
identification and kept at different conditions for stability studies. The 
study was performed in duplicate.
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b) PROCEDURE:
From the above solution serial dilutions were made to get 
40µg/ml. From this solution 0.5µl, 1.0µl, 1.5µl, 2.0µl, 2.5µl of drug 
solution was spotted corresponding to concentrations of 0.02, 0.04, 0.06, 
0.08, 0.1 µg/spot in HPTLC plates of size 10 × 10 cm and developed in a 
solvent system (Jan Krzek. et.al, 2005) comprising of Chloroform: 
methanol: 25% ammonia (4.3: 4.3: 1.4), dried and peak areas were 
measured at 277nm.  The above procedure was repeated for 5 days 
with samples withdrawn from vials kept at 5ºC, 25ºC and 45ºC at 
various time intervals of 0min, 1hrs, 2hrs, 4hrs, 6hrs, 24hrs, 72hrs, and 
120hrs respectively. The pH and clarity were also noted.  The results 
obtained were observed and recorded.
CALIBRATION GRAPH OF CIPROFLOXACIN I.V IN 
PERITONEAL DIALYSIS SOLUTION BY MICROBIOLOGICAL 
ASSAY (K.B. Method) USING E.COLI – NCIM 2911 AS TEST 
ORGANISM :
a) PREPARATION OF STOCK SOLUTION :
From 2mg/ml of Ciprofloxacin I.V infusion aliquots of 1, 2, 3, 
4,and 5 ml were taken and made up to 10 ml with peritoneal 
dialysissolution to get 200, 400, 600, 800, 1000µg /ml concentration 
respectively. 
b) PROCEDURE :
From each of the above solutions, 10µl was added to sterile disc 
to get concentration of 2, 4, 6, 8, and 10µg /disc respectively. The sterile 
discs were placed on Muller Hinton agar plates, which were previously 
swabbed by using E.coli –NCIM 2911as test organism. The plates were 
incubated for 24 hours at 37ºC and observed for zone of inhibition. The 
blank peritoneal dialysis solution containing disc was also kept and 
confirmed for no inhibitory action (zone of inhibition) against the test 
micro organism.
PROTOCOL FOR STABILITY STUDY OF CIPROFLOXACIN I.V 
IN PERITONEAL DIALYSIS SOLUTION BY MICROBIOLOGICAL 
ASSAY (K.B. Method) USING E.COLI – NCIM 2911 AS TEST 
ORGANISM :
From 2mg/ml of Ciprofloxacin I.V infusion 2ml was taken and 
made up to 10ml with peritoneal dialysis solution to get a concentration 
of 400µg /ml and were marked as 5ºC, 25ºC and 45ºC for identification 
and kept at different storage conditions for stability studies. The study 
was performed in duplicate.
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PROCEDURE :
From  the  above  solution  10µl  was  pipetted  out  to  contain  4µg  of 
Ciprofloxacin and was added to the sterile disc kept on Muller Hinton agar plates, 
which were previously swabbed by using E.coli as test organism. The plates were 
incubated for 24 hours at 37ºC and observed for zone of inhibition. The above 
procedure was repeated at various time intervals of sampling. 
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          RESULTS AND DISCUSSION
Table: 2
CALIBRATION GRAPH OF CIPROFLOXACIN HYDROCHLORIDE I.V 
USING FIRST DERIVATIVE SPECTROPHOTOMETRIC METHOD:
CONCENTRATIONS IN µg/ml ABSORBANCE AT 
263nm
2 µg/ml
4 µg/ml
6μg/ml
8μg/ml
10 µg/ml
-0.00675
-0.01251
-0.01995
-0.02564
-0.03139
Figure: 3
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Calibration graph of Ciprofloxacin IV using first derivative spectrophotometric method
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Table: 3
PHYSICAL STABILITY OF CIPROFLOXACIN HYDROCHLORIDE I.V AT THREE DIFFERENT TEMPERATURES:
Temperature
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
5ºC
pH 4.1 4.1 4.1 4.1 4.1 3.9 3.9 3.8
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
25ºC
pH 4.1 4.1 4.1 4.1 4.0 3.9 3.8 3.7
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
45ºC
pH 4.1 4.1 4.0 3.9 3.9 3.8 - -
Clarity Clear Clear Clear Clear Clear Clear - -
Color Colorless Colorless Colorless Colorless Colorless Colorless - -
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Table: 4
CHEMICAL STABILITY OF CIPROFLOXACIN HYDROCHLORIDE I.VAT THREE DIFFERENT TEMPERATURES:
(Values given below are average of two samplings)
Temp
Expected
Conc.
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
           
        5ºC 
        
8µg/ml
-0.02560
(7.99)
-0.02534
(7.91)
-0.02514
(7.85)
-0.02494
(7.79)
-0.02455
(7.67)
-0.02403
(7.51)
-0.02319
(7.25)
-0.02274
(7.11)
25ºC      8µg/ml
-0.02560
(7.99)
-0.02531
(7.90)
-0.02495
(7.79)
-0.02447
(7.64)
-0.02390
(7.46)
-0.02303
(7.19)
-0.02271
(7.09)
-0.02188
(6.83)
     
        45ºC      8 µg/ml
-0.02560
(7.99)
-0.02482
(7.75)
-0.02433
(7.60)
-0.02294
(7.17)
-0.02194
(6.86)
0.01858
(5.81) -        -
Values recorded are absorbance values and those given in brackets are concentration of ciprofloxacin in µg/ml.  Values in bold 
represents the 10% degradation from the initial concentration.
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Table: 5
DEGRADATION  PROFILE  OF  CIPROFLOXACIN  HYDROCHLORIDE 
I.VAT THREE DIFFERENT TEMPERATURES:
Sampling Time Amount of Drug Remaining (%)5ºC 25ºC 45ºC
0 time 100 100 100
1 hour 99.1 98.9 96.9
2 hour 98.4 97.5 95.1
4 hour 97.7 95.7 89.7
6hour 96.2 93.4 85.8
24 hour 94.2 90.1 72.7
72 hour 91.0 88.8 -
120 hour 89.3 85.6 -
Figure: 4
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STABILITY  STUDY  OF  CIPROFLOXACIN  HYDROCHLORIDE  I.V  AT 
THREE  DIFFERENT  TEMPERATURE  CONDITIONS  (BY  FIRST 
DERIVATIVE SPECTROPHOTOMETRIC METHOD) (E.Vega. et.al, 2001)
Ciprofloxacin  hydrochloride  I.V  (2mg/ml)  was  stored  at  different 
temperatures  such  as  room  temperature  (25ºC),  refrigeration  (5ºC)  and  45ºC. 
Samples were withdrawn at different time intervals for 5 days and quantified by 
UV first derivative spectrophotometric method. The observations at the end of 5 
days were noted.
The  stability  of  ciprofloxacin  hydrochloride  i.v  stored  at  refrigeration 
temperature proved to be more stable even after 72 hours (% deviation = 9.0) than 
the other solutions stored at room temperature (% deviation = 11.2) and 45ºC (% 
deviation = 27.3).
At 45ºC, the % deviation was > 10% (considered unstable) after nearly 2 
hours of storage (value indicates between 2-4 hours), at 25ºC > 10% degradation 
was between 24 hours and 72 hours and at 5ºC drug solution was seen between 72 
hours and 120 hours.
The  results  obtained  from  pH,  color  and  clarity  test  showed  physical 
stability at 5ºC even after 5 days.
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Table: 6
CALIBRATION  GRAPH  OF  METRONIDAZOLE  I.V  USING  FIRST 
DERIVATIVE SPECTROPHOTOMETRIC METHOD:
CONCENTRATIONS IN µg/ml ABSORBANCE AT 
299nm
2 µg/ml
4 µg/ml
6 µg/ml
8 µg/ml
10 µg/ml
-0.00239
-0.00465
-0.00667
-0.00916
-0.01135
Figure: 5
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Calibration graph of Metronidazole IV using first derivative spectrophotometric method 
53
Table: 7
PHYSICAL STABILITY OF METRONIDAZOLE I.V. AT THREE DIFFERENT TEMPERATURES:
Temperature
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
5ºC
pH 4.9 4.9 4.9 4.8 4.8 4.7 4.6 4.5
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
25ºC
pH 4.9 4.9 4.9 4.9 4.8 4.7 4.6 4.6
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
45ºC
pH 4.9 4.9 4.8 4.6 4.5 4.4 - -
Clarity Clear Clear Clear Clear Clear Clear - -
Color Colorless Colorless Colorless Colorless Colorless Colorless - -
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Table: 8
CHEMICAL STABILITY OF METRONIDAZOLE I.V. AT THREE DIFFERENT TEMPERATURES:
(Values given below are average of two samplings)
Temp
Expected
Conc.
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
           
        5ºC 
        
8µg/ml
-0.00916
(7.98)
-0.00902
(7.89)
-0.00897
(7.83)
-0.00884
(7.77)
-0.00876
(7.71)
-0.00866
(7.65)
-0.00831
(7.47)
-0.00790
(7.19)
25ºC 8µg/ml
-0.00916
(7.98)
-0.00900
(7.87)
-0.00891
(7.82)
-0.00878
(7.70)
-0.00866
(7.60)
-0.00818
(7.18)
-0.00790
(6.99)
-0.00740
(6.49)
45ºC 8µg/ml
-0.00916
(7.98)
-0.00897
(7.83)
-0.00883
(7.71)
-0.00829
(7.24)
-0.00815
(7.12)
-0.00641
(5.60) - -
Values recorded are absorbance values and those given in brackets are concentration of metronidazole I.V. in µg/ml. Values in bold 
represents the 10% degradation from the initial concentration.
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Table: 9
DEGRADATION PROFILE OF METRONIDAZOLE AT THREE DIFFERENT 
TEMPERATURES:
Sampling Time Amount of Drug Remaining (%)5ºC 25ºC 45ºC
0 time 100 100 100
1 hour 99.3 99.0 98.4
2 hour 98.6 98.4 96.9
4 hour 97.9 96.9 91.0
6hour 97.2 95.7 89.5
24 hour 96.5 90.5 70.5
72 hour 94.3 88.2 -
120 hour 90.8 81.9 -
Figure: 6
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STABILITY  STUDY  OF  METRONIDAZOLE  AT  THREE  DIFFERENT 
TEMPERATURE  CONDITIONS  (BY  FIRST  DERIVATIVE 
SPECTROPHOTOMETRIC METHOD) (E.Vega. et.al, 2001)
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Metronidazole (5mg/ml) was stored at different temperatures such as room 
temperature (25ºC), refrigeration (5ºC) and 45ºC.  Samples were withdrawn at 
different  time  intervals  for  5  days  and  quantified  by  UV  first  derivative 
spectrophotometric method.  The observations at the end of 5 days were noted.
The stability of metronidazole stored at refrigeration temperature proved 
to be more stable even after 120 hours (% deviation = 9.2) than the other solutions 
stored at room temperature (% deviation = 18.1) and 45ºC (% deviation = 29.5).
At 45ºC, the % deviation was > 10% (considered unstable) after nearly 4 
hours of storage (value indicates between 4-6 hours), at 25ºC > 10% degradation 
was between 24 hours and 72 hours and at 5ºC drug solution was stable even after 
5 days of sampling.
The  results  obtained  from  pH,  color  and  clarity  test  showed  physical 
stability at 5ºC even after 5 days.
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Table: 10
CALIBRATION GRAPH FOR SIMULTANEOUS ESTIMATION:
Concentration of ciprofloxacin is 1, 2, 3, 4 and 5µg/ml and that of metronidazole 
is 2.5, 5.0, 7.5, 10.0 and 12.5µg/ml.
RATIO OF 
CIPROFLOXACIN: 
METRONIDAZOLE
CONCENTRTION 
OF 
CIPROFLOXACIN 
AT 263 nm
CONCENTRATION 
OF 
METRONIDAZOLE 
AT 299 nm
1:2.5
2:5
3:7.5
4:10
5:12.5
-0.00328
-0.00627
-0.01004
-0.01301
-0.01766
-0.00286
-0.00611
-0.00855
-0.01118
-0.01352
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Figure: 8
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Calibration graph for Simultaneous Estimation using first derivative 
spectrophotometric method 
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Table: 11
PHYSICAL  STABILITY  OF  CIPROFLOXACIN-METRONIDAZOLE  I.V  ADMIXTURE  AT  THREE  DIFFERENT 
TEMPERATURES:
Temperature
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
5ºC
pH 4.2 4.2 4.2 4.2 4.2 4.1 4.0 3.9
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
25ºC
pH 4.2 4.2 4.1 4.1 4.0 4.0 3.9 3.8
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
45ºC
pH 4.2 4.2 4.2 4.1 4.1 4.0 - -
Clarity Clear Clear Clear Clear Clear Clear - -
Color Colorless Colorless Colorless Colorless Colorless Colorless - -
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Table: 12
CHEMICAL  STABILITY  OF  CIPROFLOXACIN-METRONIDAZOLE  ADMIXTURE  I.VAT  THREE  DIFFERENT 
TEMPERATURES: (Values given below are average of two samplings)
Temp
Expected
Conc.
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
           
        5ºC 
 Ciprofloxacin       
4µg/ml
-0.01300
(3.99)
-0.01286
(3.95)
-0.01272
(3.91)
-0.01249
(3.84)
-0.01222
(3.76)
-0.01186
(3.65)
-0.01166
(3.59)
-0.01130
(3.48)
Metronidazole
10µg/ml
-0.01112
(9.94)
-0.01105
(9.88)
-0.01083
(9.68)
-0.01071
(9.58)
-0.01063
(9.51)
-0.01039
(9.30)
-0.01021
(9.14)
-0.01000
(8.96)
25ºC
 Ciprofloxacin       
4µg/ml
-0.01300
(3.99)
-0.01277
(3.92)
-0.01254
(3.85)
-0.01244
(3.82)
-0.01212
(3.72)
-0.01169
(3.59)
-0.01117
(3.43)
-0.01097
(3.37)
Metronidazole
10µg/ml
-0.01112
(9.94)
-0.01101
(9.85)
-0.01092
(9.77)
-0.01075
(9.61)
-0.01051
(9.40)
-0.01020
(9.12)
-0.00977
(8.74)
-0.00948
(8.48)
     
        45ºC
 Ciprofloxacin       
4µg/ml
-0.01300
(3.99)
-0.01244
(3.82)
-0.01217
(3.74)
-0.01106
(3.40)
-0.01063
(3.27)
-0.00923
(2.84)
- -
Metronidazole
10µg/ml
-0.01112
(9.94)
-0.01087
(9.72)
-0.01031
(9.22)
-0.00938
(8.39)
-0.00914
(8.18)
-0.00811
(7.26)
- -
Values recorded are absorbance values and those given in brackets are concentration of ciprofloxacin-metronidazole in µg/ml. Values 
in bold represents the 10% degradation from the initial concentration.
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Table: 13
DEGRADATION PROFILE OF CIPROFLOXACIN-METRONIDAZOLE I.V ADMIXTURE AT THREE DIFFERENT 
TEMPERATURES:
Sampling 
Time
Amount of drug remaining (%)
5ºC 25ºC 45ºC
Ciprofloxacin Metronidazole Ciprofloxacin Metronidazole Ciprofloxacin Metronidazole
0 time 100 100 100 100 100 100
1 hour 99.1 99.3 98.4 99.1 95.7 97.7
2 hour 98.2 97.3 96.7 98.3 93.7 92.7
4 hour 96.7 96.4 95.8 96.7 85.2 84.4
6 hour 94.9 95.8 93.5 94.6 81.9 82.3
24 hour 92.3 93.7 90.2 91.8 71.3 73.1
72 hour 90.8 92.1 86.1 88.4 - -
120 hours 88.1 90.3 84.7 85.8 - -
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STABILITY  STUDY  OF  CIPROFLOXACIN-METRONIDAZOLE  I.V 
ADMIXTURE AT THREE DIFFERENT TEMPERATURE CONDITIONS (BY 
FIRST  DERIVATIVE  SPECTROPHOTOMETRIC  METHOD)  (E.Vega.  et.al, 
2001)
Ciprofloxacin-metronidazole  I.V  admixture  was  stored  at  different 
temperatures  such  as  room  temperature  (25ºC),  refrigeration  (5ºC)  and  45ºC. 
Samples were withdrawn at different time intervals for 5 days and quantified by 
UV first derivative spectroscopic method.  The observations at the end of 5 days 
were noted.
The stability of ciprofloxacin stored at refrigeration temperature proved to 
be more stable even after 72 hours (% deviation = 9.2) than the other solutions 
stored at room temperature (% deviation = 13.9) and 45ºC (% deviation = 28.7).
The stability of metronidazole stored at refrigeration temperature proved 
to be more stable even after 120 hours (% deviation = 9.7) than the other solutions 
stored at room temperature (% deviation = 14.2) and 45ºC (% deviation = 26.9).
At  45ºC,  the  %  deviation  of  ciprofloxacin  was  >  10%  (considered 
unstable) after nearly 2 hours of storage (value indicates between 2-4 hours), at 
25ºC > 10% degradation was seen between 24 hours and 72 hours and at 5ºC drug 
solution was stable between 72 hours and 120 hours.
At  45ºC,  the  %  deviation  of  metronidazole  was  >  10%  (considered 
unstable) after nearly 2 hours of storage (value indicates between 2-4 hours), at 
25ºC > 10% degradation was seen between 24 hours and 72 hours and at 5ºC drug 
solution was stable up to 5 days.
The  results  obtained  from  pH,  color  and  clarity  test  showed  physical 
stability at 5ºC even after 5 days.
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Table: 14
CALIBRATION  GRAPH  OF  CIPROFLOXACIN  I.V  IN  PERITONEAL 
DIALYSIS SOLUTION:
CONCENTRATION OF 
DRUG SPOTTED
VOLUME OF DRUG 
SPOTTED
PEAK AREA AT 277 
nm
0.02µg/spot
0.04µg/spot
0.06µg/spot
0.08µg/spot
0.10µg/spot
0.5µl
1.0µl
1.5µl
2.0µl
2.5µl
650.3
1243.5
1888.0
2524.1
3061.7
Figure: 11
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HPTLC CHROMATOGRAMS OF CIPROFLOXACIN I.V IN PERITONEAL 
DIALYSIS SOLUTION
Standard graph
                        
                  0.02mcg/spot                                                    0.04mcg/spot
                 
                    0.06mcg/spot                                                 0.08mcg/spot
                                       
                                                     0.1mcg/spot 
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Table: 15                                                                                       
PHYSICAL  STABILITY  OF  CIPROFLOXACIN  I.V  IN  PERITONEAL  DIALYSIS  SOLUTION  AT  THREE  DIFFERENT 
TEMPERATURES:
Temperature
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
5ºC
pH 4.6 4.6 4.6 4.6 4.6 4.4 4.4 4.4
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
25ºC
pH 4.6 4.6 4.6 4.6 4.5 4.4 4.4 4.4
Clarity Clear Clear Clear Clear Clear Clear Clear Clear
Color Colorless Colorless Colorless Colorless Colorless Colorless Colorless Colorless
45ºC
Ph 4.6 4.6 4.5 4.5 4.4 4.2 - -
Clarity Clear Clear Clear Clear Clear Clear - -
Color Colorless Colorless Colorless Colorless Colorless Colorless - -
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Table: 16
CHEMICAL  STABILITY  OF  CIPROFLOXACIN  I.V  IN  PERITONEAL  DIALYSIS  SOLUTION  AT  THREE  DIFFERENT 
TEMPERATURES : ( Values given below are average of two samplings)
Temp
Expected
Conc.
0
hour
1
hour
2
hour
4
hour
6
hour
24
hour
72
hour
120
hour
           
        5ºC 
        
0.04µg/spot
1231.0
(0.039)
1224.8
(0.038)
1218.5
(0.038)
1212.5
(0.037)
1206.1
(0.037)
1181.1
(0.035)
1156.2
(0.034)
1118.9
(0.033)
25ºC 0.04µg/spot
1231.0
(0.039)
1221.1
(0.038)
1213.7
(0.037)
1198.9
(0.036)
1185.3
(0.035)
1152.0
(0.034)
1110.1
(0.032)
1042.4
(0.030)
     
        45ºC 0.04µg/spot
1231.0
(0.039)
1206.1
(0.038)
1174.3
(0.037)
1110.8
(0.035)
1047.3
(0.033)
983.8
(0.031) -        -
Values recorded are peak area values and those given in brackets are concentration of ciprofloxacin in peritoneal dialysis solution in 
mcg/spot. Values in bold represents the 10% degradation from the initial concentration.
69
Figure : 12
HPTLC CHROMATOGRAMS OF CIPROFLOXACIN I.V IN PERITONEAL 
DIALYSIS SOLUTION AT THREE DIFFERENT TEMPERATURES
                    
                  0 time                                                              1 hour - 5ºC
          
                     1 hour - 25ºC                                             1 hour - 45ºC
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Table: 17
DEGRADATION  PROFILE  OF  CIPROFLOXACIN  IN  PERITONEAL 
DIALYSIS SOLUTION AT THREE DIFFERENT TEMPERATURES:
Sampling Time Amount of Drug Remaining (%)5ºC 25ºC 45ºC
0 time 100 100 100
1 hour 99.5 97.4 97.4
2 hour 98.98 94.8 94.8
4 hour 98.50 92.2 89.6
6hour 97.97 89.6 84.4
24 hour 95.93 84.3 79.2
72 hour 93.90 79.3 -
120 hour 90.87 74.3 -
Figure: 13
Degradation profile of ciprofloxacin 
iv in peritoneal dialysis solution at 
three different temperatures
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Table: 18 
CALIBRATION  GRAPH  OF  CIPROFLOXACIN  I.V  IN  PERITONEAL 
DIALYSIS SOLUTION BY MICROBIAL ASSAY USING  E. COLI – NCIM 
2911 AS TEST ORGANISM:
S.No
Concentration
(µg/disc)
Log
Concentration
Average diameter of  zone 
of inhibition (in mm) n=3
1. 2 0.3010 28.5
2. 4 0.6020 30.5
3. 6 0.7781 32
4. 8 0.9030 33.5
5. 10 1.0000 35.5
Figure: 14
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ZONE  OF  INHIBITION  OF  CIPROFLOXACIN  I.V  IN  PERITONEAL 
DIALYSIS  SOLUTION  BY  MICROBIOLOGICAL  ASSAY  METHOD 
USING E.COLI – NCIM 2911 AS TEST ORGANISM
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Figure : 15
ZONE  OF  INHIBITION  OF  CIPROFLOXACIN  IN  PERITONEAL 
DIALYSIS  SOLUTION  BY  MICROBIOLOGICAL  ASSAY  METHOD 
USING E.COLI – NCIM 2911 AS TEST ORGANISM.       
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Table: 19
ZONE  OF  INHIBITION 
AND 
CONCENTRATIONS 
(WITH  PERCENTAGE 
75
DEVIATION)  OF  CIPROFLOXACIN  I.V  IN  PERITONEAL  DIALYSIS 
SOLUTION BY MICROBIAL ASSAY USING E.COLI – NCIM 2911 AS TEST 
ORGANISM:
Time of
Sampling
Expected
Concentration
Diameter of zone of inhibition
Refrigeration
(5ºC)
Room
Temp (25ºC)
(45ºC)
0 4µg/10µl 30 30 30
1 hr 4µg/10µl 30 30 30
2 hr 4µg/10µl 30 30 30
4 hr 4µg/10µl 30 30 29
6 hr 4µg/10µl 30 29 28
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CONCLUSION OF WORK
Results of our study on the physical and 
chemical stability of Ciprofloxacin I.V alone (by 
stability indicating first derivative 
spectrophotometric method) found that 
Ciprofloxacin was stable for up to 5 days at  
refrigeration temperature, up to 24 hours at room 
temperature and for 4 hours at 45ºC.
Results of our study for Metronidazole I.V 
alone (by stability indicating first derivative 
spectrophotometry) found that Metronidazole 
was stable for up to 5 days at refrigeration 
temperature, up to 24 hours at room temperature 
and for 6 hours at 45ºC.
Results of our study for  stability study of  
Ciprofloxacin-Metronidazole I.V admixture (by 
stability indicating first derivative 
spectrophotometry) were found similar to those 
reported by Vega.E et.al., 2001; where the 
admixture was stable up to 5 days at refrigeration 
temperature, 24 hours at room temperature, we 
inferred from our results that the admixture was 
stable for less than 4 hours at 45ºC.
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Results of our study for stability of  
Ciprofloxacin I.V in peritoneal dialysis solution 
(by HPTLC method) were found similar to those 
reported by Kane MP et al 1994 and Mawhinney 
WM et al 1992; where Ciprofloxacin in peritoneal  
dialysis solution was stable for up to 5 days at  
refrigeration temperature and 24 hours at room 
temperature, we inferred from our results that  
Ciprofloxacin in peritoneal dialysis solution was 
stable only for 4 hours at 45ºC.
Results of our study involving Ciprofloxacin 
in peritoneal dialysis solution (quantified by 
microbiological assay method) that Ciprofloxacin 
in peritoneal dialysis solution was stable for only 
4 hours at 45ºC. Good correlation was seen 
between the HPTLC assay and microbiological  
assay used in our work for the quantification of  
ciprofloxacin in peritoneal dialysis solution. 
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